Kansas Governor Kathleen Sebelius is confirmed as HHS Secretary.
Kansas Governor Kathleen Sebelius has been confirmed and sworn in as the next Secretary of the U.S. Department of Health and Human Services (HHS).
“It is an honor to lead the Department of Health and Human Services, and I am grateful for the opportunity to serve at such a pivotal moment in our history,” she said in a statement.Secretary Sebelius has more than 20 years of experience in state government, and has been a leader on healthcare issues for over a decade. She was first elected governor of Kansas in 2003 and was re-elected in 2006.
In response to the announcement, Scott P. Serota, president and CEO of the Blue Cross and Blue Shield Assn. (BCBSA), issued a statement supporting the confirmation.
“Secretary Sebelius has long been an advocate of expanding access and making healthcare more affordable. We look forward to working with her, the Obama administration and members of Congress on comprehensive healthcare reform this year that builds on the existing employer-based system of coverage to expand coverage to all Americans and improve quality while reining-in costs,” Serota said.
At a recent House Ways and Means Committee hearing, Sebelius stressed the importance of health IT interoperability, as well as the importance of including adequate privacy protections for health data.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More